Amanda B. Payne

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024

R. Link-Gelles, F. Dawood, R. Selvarangan, 2024, MMWR. Morbidity and mortality weekly report.

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

R. Link-Gelles, F. Dawood, Uzo Chukwuma, 2024, MMWR. Morbidity and mortality weekly report.